Luisa Fernanda Figueredo

Dr. Luisa Fernanda Figueredo

Psychiatry, New York University Langone Medical Center, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
LFLeonardo José Monteiro de Macêdo Filho
Leonardo José Monteiro de Macêdo Filho
LFLuisa Fernanda Figueredo
Luisa Fernanda Figueredo
GVGustavo Adolfo Villegas-Gomez
Gustavo Adolfo Villegas-Gomez
MAMatthew Arthur
Matthew Arthur
MPMaria Camila Pedraza-Ciro
Maria Camila Pedraza-Ciro
RARobson Amorim
Robson Amorim
Traumatic Brain Injury (TBI) remains a leading cause of morbidity and mortality among all ages; despite the advances, understanding pathophysiological responses after TBI is still complex, involving multiple mechanisms. Previous reviews have focused on potential targets; however, the research on potential targets has continuously grown in the last five years, bringing even more alternatives and elucidating previous mechanisms. Knowing the key and updated pathophysiology concepts is vital for adequate management and better outcomes. This article reviews the underlying molecular mechanisms, the latest updates, and future directions for pathophysiology-based TBI management.

23 May 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
LFLuisa Fernanda Figueredo
Luisa Fernanda Figueredo
AMAndrea Liliana Martinez
Andrea Liliana Martinez
PSPaola Suarez-Meade
Paola Suarez-Meade
LMLina Marenco-hillembrand
Lina Marenco-hillembrand
ASAndrés Felipe Salazar
Andrés Felipe Salazar
JAJoao Paulo Almeida
Joao Paulo Almeida
In recent years, the endoscopic endonasal approach (EEA) for craniopharyngiomas has proven to be a safe option for extensive tumor resection, with minimal or no manipulation of the optic nerves and excellent visualization of the superior hypophyseal branches when compared to the Transcranial Approach (TCA). However, there is an ongoing debate regarding the criteria for selecting different approaches. To explore the current results of EEA and discuss its role in the management of craniopharyngiomas, we performed MEDLINE, Embase, and LILACS searches from 2012 to 2022. Baseline characteristics, the extent of resection, and clinical outcomes were evaluated. Statistical analysis was performed through an X2 and Fisher exact test, and a comparison between quantitative variables through a Kruskal–Wallis and verified with post hoc Bonferroni. The tumor volume was similar in both groups (EEA 11.92 cm3, -TCA 13.23 cm3). The mean follow-up in months was 39.9 for EEA and 43.94 for TCA, p = 0.76). The EEA group presented a higher visual improvement rate (41.96% vs. 25% for TCA, p < 0.0001, OR 7.7). Permanent DI was less frequent with EEA (29.20% vs. 67.40% for TCA, p < 0.0001, OR 0.2). CSF Leaks occurred more frequently with EEA (9.94% vs. 0.70% for TCA, p < 0.0001, OR 15.8). Recurrence rates were lower in the EEA group (EEA 15.50% vs. for TCA 21.20%, p = 0.04, OR 0.7). Our results demonstrate that, in selected cases, EEA for resection of craniopharyngiomas is associated with better results regarding visual preservation and extent of tumor resection. Postoperative CSF leak rates associated with EEA have improved compared to the historical series. The decision-making process should consider each person’s characteristics; however, it is noticeable that recent data regarding EEA justify its widespread application as a first-line approach in centers of excellence for skull base surgery.

12 December 2025 in Neurosurgery
Verified
Journal Article
Closed access
RBRonnie E. Baticulon
Ronnie E. Baticulon
JSJinno Jenkin Sy
Jinno Jenkin Sy
JHJoseline Haizel-Cobbina
Joseline Haizel-Cobbina
LDLiping Du
Liping Du
LFLuisa Fernanda Figueredo
Luisa Fernanda Figueredo
MDMichael C. Dewan
Michael C. Dewan
BACKGROUND AND OBJECTIVES: Traumatic brain injury (TBI) is a public health concern that leads to premature deaths and disability in a large number of children worldwide. The aim of this study was to estimate the global incidence of pediatric TBI and to compare the clinical presentation and outcome of pediatric TBI in different countries, regions, and income settings. METHODS: A systematic review was conducted to identify studies on pediatric patients with TBI published from 2000 onward. Studies that contained population-level data were included in meta-analyses to calculate the incidence of TBI and TBI-related mortality. Studies that reported hospital-level data were pooled to calculate mortality rates, proportion of patients with severe TBI, and proportion of TBI resulting from falls and road traffic injuries. RESULTS: The estimated global incidence of pediatric TBI was 226.4 per 100 000 children annually, using data from 25 studies in 5 regions. An estimated 1.9 per 100 000 children die from TBI each year. Based on 79 studies from 42 countries, 11.0% (median: 10.7%) of patients had severe TBI. The overall mortality rate was 1.4% (median: 3.2%). In 28 studies, the median mortality rate for severe TBI was 26.7%. Studies from low-income and middle-income countries reported higher proportions of patients with severe TBI and higher mortality rates. Road traffic injuries were the most common cause of TBI among children in Africa and in low-income countries. Falls were more common in other regions. CONCLUSION: Every year, about 5.4 million children worldwide sustain a TBI. Disparities in the estimated incidence rates of pediatric TBI among countries may represent true differences in frequency or variability in the capacity of health systems to address TBI. Population-level data remain lacking in low-income and lower-middle–income countries.

12 September 2023 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
LFLuisa Fernanda Figueredo
Luisa Fernanda Figueredo
WSWilliam J. Shelton
William J. Shelton
UTUriel Tagle-Vega
Uriel Tagle-Vega
ESEmiliano Sanchez
Emiliano Sanchez
LFLeonardo de Macedo Filho
Leonardo de Macedo Filho
JAJoao Paulo Almeida
Joao Paulo Almeida

1 October 2019 in World Neurosurgery: X
Verified
Journal Article
Open access
LFLuisa Fernanda Figueredo
Luisa Fernanda Figueredo
MPMaría Camila Pedraza-Ciro
María Camila Pedraza-Ciro
JLJuan Lopez-McCormick
Juan Lopez-McCormick
RRRoberto Javier Rueda-Esteban
Roberto Javier Rueda-Esteban
JMJuan Armando Mejía-Cordovez
Juan Armando Mejía-Cordovez
Previous studies have shown low rupture rates for small aneurysms (<10 mm), suggesting that the risk of treatment could exceed the benefits. However, evidence has changed, showing crescent rates of aneurysmal subarachnoid hemorrhage (aSAH) associated with small aneurysms. We report trends in size, localization, clinical characteristics, and outcomes of intracranial aneurysms (IAs). In this retrospective study, a total of 200 clinical histories of patients diagnosed with IAs over an 8-year period were analyzed. Variables considered included age, sex, tobacco consumption, morphological characteristics of the aneurysm, complications, vasospasm, and mortality. Qualitative variables were assessed by measurements of absolute and relative frequency. Smoking behavior, aneurysm size, and aneurysm rupture (AR) were compared using 1-way analysis of variance. Categorical variables were analyzed using Pearson's χ2 test. The average age at presentation was 58 years. The average size of ruptured aneurysms in the general group was 2.5-7.5 mm, and AR was most common in women (76%) and in patients age 50-60 years (33%). The rate of vasospasm was 19%, and mortality was 37%. Smokers composed 32% of the cohort. Heavy smokers had a 57% rate of aSAH, with an average size of rupture of 5 mm. The most common location of aneurysms and AR was the AComA (33%). Our results suggest increasing AR rates in aneurysms smaller than 10 mm. This trend is seen especially in individuals with heavy tobacco consumption and in women of perimenopausal age. Our findings show a tendency of AR in accordance with previous results and are expected to serve as basis for further research on aneurysm management.

30 June 2023 in Surgical Neurology International
Verified
Journal Article
Open access
Edgar G. Ordóñez-RubianoEdgar G. Ordóñez-Rubiano
Edgar G. Ordóñez-Rubiano
MBMatias Baldoncini
Matias Baldoncini
ACAlba Lucía Combita
Alba Lucía Combita
CPCesar Payan
Cesar Payan
DGDiego Gomez-Amarillo
Diego Gomez-Amarillo
RPRafael Parra-Medina
Rafael Parra-Medina
Background: Gliomas represent almost 30% of all primary brain tumors and account for 80% of malignant primary ones. In the last two decades, significant progress has been made in understanding gliomas’ molecular origin and development. These advancements have demonstrated a remarkable improvement in classification systems based on mutational markers, which contribute paramount information in addition to traditional histology-based classification. Methods: We performed a narrative review of the literature including each molecular marker described for adult diffuse gliomas used in the World Health Organization (WHO) central nervous system 5. Results: The 2021 WHO classification of diffuse gliomas encompasses many molecular aspects considered in the latest proposed hallmarks of cancer. The outcome of patients with diffuse gliomas relies on their molecular behavior and consequently, to determine clinical outcomes for these patients, molecular profiling should be mandatory. At least, the following molecular markers are necessary for the current most accurate classification of these tumors: (1) isocitrate dehydrogenase (IDH) IDH-1 mutation, (2) 1p/19q codeletion, (3) cyclin-dependent kinase inhibitor 2A/B deletion, (4) telomerase reverse transcriptase promoter mutation, (5) α-thalassemia/ mental retardation syndrome X-linked loss, (6) epidermal growth factor receptor amplification, and (7) tumor protein P53 mutation. These molecular markers have allowed the differentiation of multiple variations of the same disease, including the differentiation of distinct molecular Grade 4 gliomas. This could imply different clinical outcomes and possibly impact targeted therapies in the years to come. Conclusion: Physicians face different challenging scenarios according to the clinical features of patients with gliomas. In addition to the current advances in clinical decision-making, including radiological and surgical techniques, understanding the disease’s molecular pathogenesis is paramount to improving the benefits of its clinical treatments. This review aims to describe straightforwardly the most remarkable aspects of the molecular pathogenesis of diffuse gliomas.